INTRACEL Sample Clauses

INTRACEL shall keep and shall require its Affiliates and sublicensees to keep complete and accurate records of the sales of each Product and all data necessary for the computation of payments to be made to TJU hereunder. TJU shall have the right to nominate an independent Certified Public Accountant who shall have access to INTRACEL's records and those of its Affiliates and sublicensees during reasonable business hours for the purpose of verifying the payments made under this Agreement, but this right may not be exercised more than once in any year, and the accountant shall disclose to TJU only information relating to the accuracy of the payment report and the payments made in accordance with this Agreement, and the reasons for any discrepancy.
Sample 1Sample 2
AutoNDA by SimpleDocs
INTRACEL shall use its best efforts to develop and market Products. At the end of each Agreement Year, INTRACEL shall provide TJU with a written report detailing INTRACEL's efforts to develop and market Products during that year.
Sample 1Sample 2
INTRACEL shall take all appropriate steps to ensure that, if eligible, TJU will be able to obtain patent term extensions) pursuant to 35 U.S.C.156 et seq., as appropriate. INTRACEL shall keep TJU fully informed with respect to its submissions to governmental authorities for regulatory review for Products which may be eligible for patent term extension. INTRACEL acknowledges that time is of the essence with respect to submission of the application for patent term extension. INTRACEL shall send written notice to TJU within three (3) business days of the date a Product receives permission under the provision of the law under which the applicable regulatory review period occurred for commercial marketing or use ("Approval Date"). INTRACEL shall provide all necessary information in its possession and reasonable assistance in preparing an application, if TJU is eligible, for patent term extension in compliance with 35 U.S.C. 156 et. seq. and any applicable governmental regulations within thirty (30) days after Approval Date. INTRACEL agrees to cooperate fully with TJU in preparing such application for patent term extension. If eligible, TJU shall file, in their own name, such application for patent term extension. INTRACEL, if requested, agrees to join in such application for patent term extension. INTRACEL shall fully support such application and shall provide such information as may reasonably be requested in support of the application by TJU or by the government.
Sample 1Sample 2
INTRACEL and TJU shall not use the name of the other or the names of any of the other's staff members, employees or students or any adaptation thereof in any advertising, promotional or sales literature to the extent such use might imply a relationship between the parties or approval or endorsement by TJU of any Product or method described in any such literature without the prior written approval of the other party, which will not be unreasonably withheld.
Sample 1Sample 2
INTRACEL. INTRACEL CORPORATION By:__________________________________ Name:________________________________ Title:_______________________________ LEHIGH: LEHIGH VALLEY HOSPITAL AND HEALTH NETWORK By:__________________________________ Name:________________________________ Title:_______________________________ CERTIFICATE OF INCORPORATION OF INTRACEL CANCER CENTER OF PENNSYLVANIA, INC.
Sample 1
INTRACEL. INTRACEL CORPORATION By:__________________________________ Name:________________________________ Title:_______________________________ LEHIGH: LEHIGH VALLEY HOSPITAL AND HEALTH NETWORK By:__________________________________ Name:________________________________ Title:_______________________________
Sample 1
INTRACEL. Registration County No. Date Filed Status --------------- ------------ ---------- ----------------------------------- Australia 608813 08/09/93 Pending Benelux 537216 08/11/93 Registered 817640487 08/01/93 Pending; reg'n fee paid 6/19/95 Brazil Canada 734,661 08/09/93 Pending; response to OA due 12/7/95 China 93073886 08/26/93 Pending; published in OG 11/21/94 France 93479055 08/03/93 Registered Germany Z 11488/10 Wz 08/11/93 Pending; published in OG 10/31/91 Greece 116498/93 09/29/93 Pending Israel 88567 08/12/93 Pending Italy RM93C/002727 08/18/93 Pending Japan 82,893/1993 08/10/93 Pending Mexico 175,387 08/13/93 Registered 4/28/94; Reg. No. 458,743 South Korea 93-28412 08/11/93 Registered 11/2/94; Reg. No. 301300 Xxxxx 1,779,240 09/09/93 Pending Switzerland 2857/1994.7 04/27/94 Pending Taiwan 82039743 08/13/93 Registered 8/16/94; Reg. No. 649200 Xxxxxxxx 253401 10/08/93 Pending; published in OG 4/21/95 United Kingdom 1,544,180 08/09/93 Registered 12/16/94; Reg. No. 1,544,180 United States TRADEMARK LICENSES Item B. None. 317 Item A. Trademarks
Sample 1
AutoNDA by SimpleDocs

Related to INTRACEL

  • Insulin Insulin will be treated as a prescription drug subject to a separate copay for each type prescribed.

  • Influenza Vaccine Upon recommendation of the Medical Officer of Health, all employees shall be required, on an annual basis to be vaccinated and or to take antiviral medication for influenza. If the costs of such medication are not covered by some other sources, the Employer will pay the cost for such medication. If the employee fails to take the required medication, she may be placed on an unpaid leave of absence during any influenza outbreak in the home until such time as the employee has been cleared by the public health or the Employer to return to the work environment. The only exception to this would be employees for whom taking the medication will result in the employee being physically ill to the extent that she cannot attend work. Upon written direction from the employee’s physician of such medical condition in consultation with the Employer’s physician, (if requested), the employee will be permitted to access their sick bank, if any, during any outbreak period. If there is a dispute between the physicians, the employee will be placed on unpaid leave. If the employee gets sick as a reaction to the drug and applies for WSIB the Employer will not oppose the application. If an employee is pregnant and her physician believes the pregnancy could be in jeopardy as a result of the influenza inoculation and/or the antiviral medication she shall be eligible for sick leave in circumstances where she is not allowed to attend at work as a result of an outbreak. This clause shall be interpreted in a manner consistent with the Ontario Human Rights Code.

  • Hepatitis B Vaccine Where the Hospital identifies high risk areas where employees are exposed to Hepatitis B, the Hospital will provide, at no cost to the employees, a Hepatitis B vaccine.

  • API If the Software offers integration capabilities via an API, your use of the API may be subject to additional costs or Sage specific policies and terms and conditions (which shall prevail in relation to your use of the API). You may not access or use the API in any way that could cause damage to us or the Software, or in contravention of any applicable laws. We reserve the right in our sole discretion, to: (i) update any API from time to time; (ii) place limitations around your use of any API; and (iii) deny you access to any API in the event of misuse by you or to otherwise protect our legitimate interests.

  • Vaccinations (1) Employees shall be provided with free influenza vaccination once annually.

  • Radiation Therapy/Chemotherapy Services This plan covers chemotherapy and radiation services. Respiratory Therapy This plan covers respiratory therapy services. When respiratory services are provided in your home, as part of a home care program, durable medical equipment, supplies, and oxygen are covered as a durable medical equipment service.

  • PRODUCT MANUFACTURER'S SUPPLIERS Only those dealers/distributors listed by the manufacturer will be considered authorized to act on behalf of the Product Manufacturer.

  • Nepotism No employee shall be awarded a position where he/she is to be directly supervised by a member of his/her immediate family. “

  • Vaccine Passports Pursuant to Texas Health and Safety Code, Section 161.0085(c), Contractor certifies that it does not require its customers to provide any documentation certifying the customer’s COVID-19 vaccination or post-transmission recovery on entry to, to gain access to, or to receive service from the Contractor’s business. Contractor acknowledges that such a vaccine or recovery requirement would make Contractor ineligible for a state-funded contract.

  • Vaccination and Inoculation (a) The Employer agrees to take all reasonable precautions, including in-service seminars, to limit the spread of infectious diseases among employees.

Time is Money Join Law Insider Premium to draft better contracts faster.